Claims for Patent: 8,435,516

Summary for Patent: 8,435,516

Title:	Cancer treatment
Abstract:	The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subjects response to a cancer treatment.
Inventor(s):	Huang; Bo (New London, CT), Marshall; Margaret Ann (Waterford, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	13/501,730
Patent Claims:	1. A method of treating melanoma, comprising the steps of: a) selecting a subject with a serum CRP concentration that is less than or equal to 1.5 times the upper-limit-of-normal value; and b) administering an anti-CTLA4 antibody or an antigen-binding portion thereof to said subject. 2. A method of treating melanoma, comprising the steps of: a) determining the serum CRP concentration in a subject in a CRP assay; b) selecting a subject with a serum CRP concentration that is less than or equal to 1.5 times the upper-limit-of-normal value as determined by said CRP assay; and c) administering an anti-CTLA4 antibody or an antigen-binding portion thereof to the selected subject. 3. A method of predicting a benefit to a melanoma patient of an immunotherapy treatment using an anti-CTLA-4 antibody or an antigen-binding portion thereof, over a chemotherapy treatment, comprising: a) measuring the serum CRP concentration in the patient in a CRP assay; b) comparing said serum CRP concentration to the upper-limit-of-normal (ULN) value as determined by the CRP assay, wherein a serum CRP concentration in the patient of less than or equal to 1.5 times the ULN value is indicative of a benefit to the patient of the immunotherapy treatment over a chemotherapy treatment. 4. The method of claim 3, wherein the benefit is an improvement in overall survival. 5. The method of claim 1 or 3, wherein said melanoma is unresectable stage IV melanoma. 6. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises the heavy and light chain CDR sequences set forth in SEQ ID NOs: 17, 18, 19, 20, 21, and 22. 7. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises the heavy and light chain CDR sequences set forth in SEQ ID NOs: 25, 26, 27, 28, 29, and 30. 8. The method of claim 6, wherein said antibody is tremelimumab. 9. The method of claim 7, wherein said antibody is ipilimumab. 10. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises the heavy and light chain CDR sequences set forth in: a) SEQ ID NOs: 1, 2, 3, 4, 5, and 6; or b) SEQ ID NOs: 9, 10, 11, 12, 13, and 14. 11. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain comprising the amino acid sequence of SEQ ID NO: 8. 12. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and a light chain comprising the amino acid sequence of SEQ ID NO: 16. 13. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 23 and a light chain comprising the amino acid sequence of SEQ ID NO: 24. 14. The method of claim 1 or 3, wherein said anti-CTLA4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid sequence of SEQ ID NO: 32.

Details for Patent 8,435,516

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2039-02-26